Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases

Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases

The Special Issue of Biomedicines, entitled "Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases," presents cutting-edge research findings, innovations, and insights into a wide range of topics related to the hepatobiliary system, such as the molecular mechanisms underlying...

Full description

Bibliographic Details
Format:	eBook
Language:	English
Published:	Basel MDPI - Multidisciplinary Digital Publishing Institute 2023
Subjects:	Medicine AAV autoantibodies biomarker budesonide cholestatic diseases chronic hepatitis B cirrhosis DAA deletions farnesoid X receptor fatty liver females fibrates fibrosis score FXR agonists gender gene therapy genotoxicity glycoprotein gp210 HBX 3' end region HCV hepatic steatosis hepatitis B virus hepatitis B X open reading frame hepatocellular carcinoma insertions KLHL12 peptide liver liver fibrosis metabolism miR-125b mitochondria n/a NAFLD NASH next-generation sequencing non-alcoholic fatty liver disease nucleoporin p62 nucleos(t)ide analogs obeticholic acid obeticholic acid (OCA) PBC PFIC PPAR agonists primary biliary cholangitis quasispecies radiofrequency ablation RUNX1 side effect systems biology transarterial chemoembolization transient hepatic elastography type 2 diabetes mellitus ursodeoxycholic acid ursodeoxycholic acid (UDCA)
Online Access:	Open Access: DOAB: description of the publication Open Access: DOAB, download the publication

Similar Items

Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis
by: Floreani A
Published: (2020-12-01)

Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection
by: Bowlus CL
Published: (2016-09-01)

Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
by: Ludovico Abenavoli, et al.
Published: (2018-10-01)

May Ursodeoxycholic Acid Significantly Improve Liver Function Tests among Patients with Hepatitis C?
by: Alpaslan Tanoglu, et al.
Published: (2015-12-01)

Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases
by: Vik Meadows, et al.
Published: (2020-01-01)

Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury
by: Anca D. Petrescu, et al.
Published: (2021-07-01)

Primary biliary cholangitis
by: I. M. Iljinsky, et al.
Published: (2021-04-01)

Protective Effects of Ursodeoxycholic Acid on Valproic Acid Induced Hepatotoxicity in Epileptic Children with Recurrent Seizure; A Double-Blinded Randomized Clinical Trial
by: Iraj Shahramian, et al.
Published: (2020-03-01)

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
by: Jhaveri MA, et al.
Published: (2017-08-01)

On the Pharmacology of Farnesoid X Receptor Agonists: Give me an “A”, Like in “Acid”
by: Eva Hambruch, et al.
Published: (2016-06-01)

Serum metabolite profiles are associated with the presence of advanced liver fibrosis in Chinese patients with chronic hepatitis B viral infection
by: Guoxiang Xie, et al.
Published: (2020-06-01)

Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): applying the cut-offs of M probe to XL probe
by: Grace Lai-Hung Wong, et al.
Published: (2013-07-01)

Liver Fibrosis: A Clinical Update
by: Lindsey C. Shipley, et al.
Published: (2019-05-01)

Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease
by: Sun-Gi Kim, et al.
Published: (2016-12-01)

The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities
by: Marta Mazzetti, et al.
Published: (2021-04-01)

Ursodeoxycholic Acid Can Improve Liver Transaminase Quantities in Children with Anticonvulsant Drugs Hepatotoxicity: a Pilot Study
by: Masoumeh Asgarshirazi, et al.
Published: (2015-06-01)

Study of Hepatoprotective Effect of Silymarin and Ursodeoxycholic Acid in Chronic Hepatitis C Patients
by: Shahira Fawzy El Menshawe, et al.
Published: (2014-12-01)

Diagnostic Performance of Serum Asialo-α1-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease
by: Seung Up Kim, et al.
Published: (2019-12-01)

Assessment of hepatic fibrosis and necroinflammation among inactive HBsAg carriers in Egypt
by: Amr Abdelkader Fateen, et al.
Published: (2012-07-01)

Optimization of therapy for hepatobiliary disorders in psoriatic patients
by: I V Kozlova, et al.
Published: (2017-12-01)

Relevance of reactive oxygen species in liver disease observed in transgenic mice expressing the hepatitis B virus X protein
by: Dae-Yeul Yu
Published: (2020-02-01)

Serum hyaluronic acid as a noninvasive marker of hepatic fibrosis in chronic hepatitis B
by: Geramizadeh Bita, et al.
Published: (2008-01-01)

Pruritus in chronic cholestatic liver diseases
by: E. V. Vinnitskaya, et al.
Published: (2017-12-01)

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
by: Ludovico Abenavoli, et al.
Published: (2020-06-01)

The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced
by: Antonio Vitiello, et al.
Published: (2021-01-01)

Real-time tissue elastography in the evaluation of liver cirrhosis in patients with chronic hepatitis B
by: Zhan-Fang Wei, et al.
Published: (2016-08-01)

The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B
by: In Ku Yo, et al.
Published: (2015-03-01)

Surveillance for hepatocellular carcinoma in patients with advanced liver fibrosis
by: Angelo Sangiovanni, et al.
Published: (2021-01-01)

Impact of Fibroscan® on management of chronic viral hepatitis in clinical practice
by: Dietje Fransen van de Putte, et al.
Published: (2011-10-01)

Epidemiologic and Therapeutic Aspects of Chronic Diffuse Liver Diseases in Servicemen
by: G.V. Osyodlo
Published: (2013-11-01)

<b>Analytical methods for evaluation of the fatty acid metabolism in rat liver
by: Eduardo Hideo Gilglioni, et al.
Published: (2018-11-01)

Metabolomic Study of High-Fat Diet-Induced Obese (DIO) and DIO Plus CCl<sub>4</sub>-Induced NASH Mice and the Effect of Obeticholic Acid
by: Nanlin Zhu, et al.
Published: (2021-06-01)

The Increased Level of Serum p53 in Hepatitis B-Associated Liver Cirrhosis
by: Parisa Shahnazari, et al.
Published: (2014-09-01)

Ultrasound-Based Liver Stiffness Surveillance in Patients Treated for Chronic Hepatitis B or C
by: Sheng-Hung Chen, et al.
Published: (2018-04-01)

Evaluation of hepatic fibrosis parameter model and elastic modulus of liver and spleen for the diagnosis of hepatic fibrosis in chronic hepatitis b
by: Wei-Ting Lu
Published: (2020-05-01)

慢性乙型肝炎患者血清脂联素水平及其与代谢指标的关系
by: PENG Hong
Published: (2014-04-01)

Comparison of Liver Biopsy with Hepascore in Patients with Hepatitis C-Genotype 1
by: Hamid Klantari, et al.
Published: (2011-06-01)

Serum hyaluronic acid as a noninvasive marker of hepatic fibrosis in chronic hepatitis c patients
by: Soheir M Abd-Elghany, et al.
Published: (2016-01-01)

The diagnostic value of indirect markers of liver fibrosis in patients with chronic hepatitis B
by: D. V. Tereshkov, et al.
Published: (2020-03-01)

Cholestasis syndrome in a comorbid patient: diagnostic difficulties
by: E. V. Vinnitskaya, et al.
Published: (2019-10-01)

Cannot write session to /tmp/vufind_sessions/sess_srk69q5nq2en3mmfhcil9qk49f